Business
MiNK Therapeutics Reports First Quarter 2026 Financial Results and Advances iNKT Cell Therapy Platform Into Randomized Clinical Validation
Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung diseaseNon-dilutive collaborations expand MiNK’s platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programsCompany continues disciplined execution with reduced op
About this update from Mink Therapeutics, Inc.
[{"type":"image","alt":"MiNK Therapeutics","displaySize":"","headline":null,"caption":"MiNK Therapeutics","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/i_32n6NFUT7JH9rPdqYNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116},"resize_sm":{"url":"https://s.yimg.com/ny/api/res/1.2/i_32n6NFUT7JH9rPdqYNHQ--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2Mg--/https://media.zenfs.com/en/globenewswire.com/4b1b28678bcbc056b777d0ad1341f645","width":300,"height":116}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"Randomized Phase 2 trial initiated for agenT-797 in severe acute lung injury and respiratory distress, with preliminary data expected in the second half of 2026","length":160,"tagName":"p"}]},{"val":[{"type":"text","content":"AACR and ASGCT presentations showcase durable survival and context-dependent iNKT activity in cancer and inflammatory lung disease","length":130,"tagName":"p"}]},{"val":[{"type":"text","content":"Non-dilutive collaborations expand MiNK’s platform and potentiate meaningful commercial revenue potential, while preserving focus on lead clinical programs","length":155,"tagName":"p"}]},{"val":[{"type":"text","content":"Company continues disciplined execution with reduced operating burn and focused advancement of high-priority programs","length":117,"tagName":"p"}]},{"val":[{"type":"text","content":"New clinical data to be presented at the ATS conference on May 20, 2026","length":71,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":633,"olType":false},{"type":"text","content":"NEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- MiNK Therapeutics, Inc. (NASDAQ: INKT), a clinical-stage biopharmaceutical company developing allogeneic invariant natural killer T (allo-iNKT) cell therapies to restore immune balance and treat immune-mediated diseases and cancer, today reported financial results for the first quarter ending March 31, 2026, and provided a corporate update.","length":385,"tagName":"p"},{"type":"text","content":"“MiNK entered 2026 focused on converting a growing body of clinical and translational evidence into prospective validation,” said Jenni...